This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.
Adipotide (10 mg Vial)
Adipotide is a synthetic peptidomimetic that targets prohibitin on blood vessels within white adipose tissue and delivers a pro-apoptotic sequence to destroy those vessels[1][2], resulting in targeted fat mass reduction as fat cells lose their blood supply[8].
Quick Reference
What is Adipotide?
Research overview based on the cited scientific literature.
• Goal: Targeted reduction of fat mass via vascular targeting in adipose tissue[2][8].
• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw[5].
Storage Instructions
Proper storage preserves peptide quality.
• Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure[5].
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); prepare aliquots if needed and avoid freeze–thaw[5].
• Allow vials to reach room temperature before opening to reduce condensation uptake.
How is Adipotide studied?
Adipotide is a peptidomimetic compound designed to selectively target blood vessels within white adipose tissue by binding to prohibitin-1 on the vascular endothelium[2][8]. Once bound, it delivers a pro-apoptotic sequence that triggers vessel destruction, cutting off the blood supply to fat cells and causing them to undergo apoptosis and be metabolized[1][2]. Preclinical studies in obese rodents demonstrated approximately 30% body weight reduction, and obese primates showed about 11% weight loss after 4 weeks of treatment[1][9]. A sponsor announced initiation of a phase 1 trial in patients with castrate-resistant prostate cancer, but the cited announcement reports the study design rather than results[3]. In the primary rhesus-monkey study, renal injury and altered tubular function were described as relatively mild, predictable and reversible[1]. These animal findings do not establish human safety.
What does the research report about Adipotide?
Observations from preclinical literature and limited human data.
• Preclinical studies showed notable targeted fat mass reduction (up to 30% body weight in rodents, ~11% in primates over 4 weeks)[1][2][8][9].
• Mechanism specifically targets adipose tissue vasculature, sparing other tissues in preclinical models[2].
• In the primary obese-rhesus-monkey study, renal injury and altered tubular function were the main reported safety signal and were described as relatively mild, predictable and reversible[1]. This is non-human evidence.
• Mild injection-site reactions (redness, swelling) may occur with subcutaneous administration.
• Human evidence remains unresolved in the cited sources: the sponsor announcement documents trial initiation and design, not published outcomes[3].
Important Note
This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.
What are the limitations of the research on Adipotide?
Evidence should be interpreted within the population, experimental model, formulation, route, outcome measures, and study design used in each cited source. Preclinical or early-stage findings do not establish clinical efficacy, safety, or approved human use. Where human evidence is available, results should not be generalized beyond the populations and conditions actually studied.
